Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24
- None.
- None.
From a cardiological perspective, the acceptance of the TELE-ACS trial results for a presentation at a high-profile event such as the ACC 24 signifies a potentially transformative advancement in cardiovascular patient care. The study's focus on remote assessment of high-risk patients post-acute coronary syndrome (ACS) could herald a new era in managing chronic cardiovascular conditions. The utilization of SHL's SmartHeart® technology—a 12-lead ECG system designed for home use—may enhance patient outcomes by providing continuous monitoring capabilities, thereby enabling early detection of recurrent events or complications.
Moreover, the implications of such a study are vast, potentially reducing hospital readmission rates and associated healthcare costs. The ability to remotely monitor and assess patients could translate into more personalized and timely interventions, possibly improving the long-term prognosis for individuals with cardiovascular diseases. However, the adoption of such technology will require careful consideration of its accuracy, reliability and integration into existing healthcare frameworks.
The spotlight on the TELE-ACS trial underscores the growing significance of telemedicine in the healthcare sector, particularly in chronic disease management. As a healthcare technology analyst, it is clear that the integration of SHL's SmartHeart® technology into patient care protocols could potentially disrupt traditional healthcare delivery models. The trial's results might influence both the demand for remote monitoring devices and the regulatory landscape surrounding telemedicine.
Investors and stakeholders within the telemedicine sector should closely monitor the outcomes of this trial, as positive results could drive increased adoption and possibly lead to expansion into other areas of remote patient care. It is crucial to analyze the scalability of such technologies and their interoperability with other digital health platforms. The implications for SHL Telemedicine Ltd. could be substantial, affecting its market position, strategic partnerships and long-term growth trajectory.
From a market research standpoint, the selection of the TELE-ACS trial for presentation at a prestigious conference is indicative of the market's appetite for innovative solutions in telehealth. This event could serve as a catalyst for SHL Telemedicine's growth, influencing investor perceptions and market sentiment. The successful implementation of SHL's technology in high-stakes clinical scenarios, such as post-acute coronary syndrome management, could open up new market segments and drive competitive advantage.
It is essential to evaluate the potential market size for SHL's SmartHeart® technology and related telemedicine services. Factors such as the aging population, the prevalence of cardiovascular diseases and the shift towards home-based healthcare solutions will play a critical role in determining the market opportunity. Additionally, the outcome of the trial may prompt payers and insurance companies to reconsider coverage policies for telemedicine services, which would have a significant impact on the industry's revenue streams.
The selection of the TELE-ACS trial results for presentation at ACC 24 highlights the pioneering achievements of Imperial College London and SHL in advancing the field of telemedicine
The full results of the TELE-ACS trial, led by Dr. Ramzi Khamis and Nasser S Alshahrani, will be presented on April 6, 2024, in session 403-16, titled: “Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome”. The TELE-ACS trial is a pivotal study that marks a significant milestone in telemedicine and cardiovascular care. Accepted for presentation at the prestigious ACC 24 conference, this clinical trial explores the effectiveness of remote assessment in patients with high cardiovascular risk following an acute coronary syndrome, focusing on the application of SHL's SmartHeart® 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home.
Erez Nachtomy, CEO of SHL Telemedicine, commented: “We would like to congratulate the team at Imperial College London on the acceptance of the TELE-ACS trial results for presentation at ACC 24. This achievement is a testament to the researchers and their rigorous effort to conduct this groundbreaking work. We very much look forward to seeing the presentation at ACC 24 which will share the embargoed full trial results with the global cardiology community.”
ACC 24 Participants are invited to add the session to their itinerary using the following link: https://www.abstractsonline.com/pp8/#!/10973/presentation/22832
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131123982/en/
Fabienne Farner, IRF, Phone : +41 43 244 81 42, farner@irf-reputation.ch
Source: SHL Telemedicine Ltd.
FAQ
What is the ticker symbol for SHL Telemedicine Ltd.?
What are the full results of the TELE-ACS trial focused on?
When and where will the TELE-ACS trial results be presented?
What technology does the TELE-ACS trial explore for monitoring post-MI patients at home?
Who is the CEO of SHL Telemedicine?
